A protein-based SARS-CoV-2 vaccine (IMAGE)
Caption
Shown at far left, the vaccine consists of a portion of the spike protein’s receptor-binding domain (RBD), shown in dark blue, attached to a single domain antibody-fragment that recognizes class II major histocompatibility complex (MHC) proteins, shown as orange ovals. These conjugates home to antigen-presenting cells (APCs), which then process and display the RBD to T and B cells. This leads to a robust immune response, eliciting both T cells and high titers of neutralizing antibodies that are protective across SARS-CoV-2 variants.
Credit
Novalia Pishesha, Boston Children’s Hospital
Usage Restrictions
Please credit as indicated.
License
Original content